NYSEMKT: OGENOragenics Inc Stock
$1.09+0.03 (+2.83%)
Updated Apr 23, 2024
OGEN Price
$1.09
Fair Value Price
N/A
Market Cap
$4.88M
52 Week Low
$1.02
52 Week High
$7.74
P/E
-0.12x
P/B
1.54x
P/S
336.16x
PEG
N/A
Dividend Yield
N/A
Revenue
$37.65k
Earnings
-$20.66M
Gross Margin
100%
Operating Margin
-54,776.9%
Profit Margin
-54,858.1%
Debt to Equity
0.57
Operating Cash Flow
-$7M
Beta
0.59
Next Earnings
May 10, 2024
Ex-Dividend
N/A
Next Dividend
N/A
OGEN Overview
Oragenics, Inc. is a biopharmaceutical company, which focuses on the development of novel antibiotics and treatments against infectious disease and oral mucositis. The company is headquartered in Tampa, Florida and currently employs 12 full-time employees. The firm is focused on offering antibiotics against infectious disease and on developing treatments for oral mucositis. The company is engaged in developing its antibiotic product candidate, MU1140, as well as other homolog antibiotic product candidates; researching AG013 in connection with the treatment of Oral Mucositis; commercializing its ProBiora3 probiotic products, and has other product candidates for out licensing or partnering. MU1140 is an antibiotic that is produced by the parent of the SMaRT strain. ProBiora3 is a blend of three naturally occurring strains of beneficial bacteria, including Streptococcus oralis KJ3, Streptococcus uberis KJ2 and Streptococcus rattus JH145. LPT3-04 is a compound, which is consumed in the human diet in small amounts and results in dose-dependent weight loss in experimental animal models.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how OGEN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OGEN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
OGEN is good value based on its book value relative to its share price (1.54x), compared to the US Biotechnology industry average (5.93x)
P/B vs Industry Valuation
OGEN is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more OGEN due diligence checks available for Premium users.
Be the first to know about important OGEN news, forecast changes, insider trades & much more!
OGEN News
Valuation
OGEN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.12x
Industry
16.46x
Market
41.92x
OGEN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.54x
Industry
5.93x
OGEN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
OGEN's financial health
Profit margin
Revenue
$0.0
Net Income
-$12.7M
Profit Margin
0%
OGEN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
OGEN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$5.0M
Liabilities
$1.8M
Debt to equity
0.57
OGEN's short-term assets ($3.87M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OGEN's short-term assets ($3.87M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OGEN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
OGEN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.1M
Investing
-$1,000.0k
Financing
-$180.6k
OGEN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
OGEN vs Biotech Stocks
Oragenics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.